What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Semax/P21-family adamantane-modified nootropic (reference name) · exact molecular specification not independently confirmed
Overview
Adamax is a synthetically enhanced derivative of Semax (a Russian-developed neuropeptide drug based on the ACTH 4-10 fragment), modified with N-terminal acetylation and a C-terminal adamantane group (borrowed from the "Peptide 021"/P21 structure) intended to improve metabolic stability and blood-brain-barrier penetration. It is not a product of formal pharmaceutical R&D but originated as a "community-modified" formulation first synthesized and sold on the gray research-chemical market by the US supplier Ceretropic sometime between 2015 and 2018 (multiple consumer/community sources consistently state the company closed in 2018); it has since been replicated by other independent labs. Online claims naming a specific developer or citing a precise 2016-2017 development timeline could not be independently verified and should be treated with caution. The compound is not currently listed in authoritative chemical databases such as PubChem, DrugBank, or NCATS Inxight Drugs/GSRS (a July 2026 re-check by name, InChIKey, and molecular formula found no genuine matching PubChem record), and it lacks peer-reviewed human or animal studies — it appears only on research-grade vendor sites and enthusiast-community material, representing a very low evidence tier. Worth noting: an English Wikipedia article titled "Adamax" does genuinely exist (created October 2025, edited several times through May 2026), but it is extremely thin — a single descriptive sentence plus a chemical infobox — and its sole citation is the same Medsafe document discussed below, so it does not constitute evidence independent of that regulatory filing. Notably, New Zealand's medicines regulator Medsafe named Adamax alongside Semax as a representative example of an "ACTH analogue" in a June 2025 submission to its Medicines Classification Committee proposing prescription-medicine scheduling, citing nootropic marketing claims, border interceptions, and lack of clinical data; this review independently re-fetched the primary Medsafe minutes document (the official 74th meeting minutes, dated 23 July 2025, at https://www.medsafe.govt.nz/profs/class/Minutes/2021-2025/74mccMin23July2025.htm) and confirmed the proposal was indeed reviewed at that meeting, with the minutes explicitly recording that the committee decided on "deferring the decision pending additional information," after which the secretariat recommended prescription-medicine classification. A previous version of this profile had mistakenly judged this meeting record as unsubstantiated and removed it; it has now been verified and restored. As of the most recent verifiable information, no official announcement finalizing Adamax as a scheduled/prescription substance could be found. This product is for research use only (RUO) and is not intended for human use. Vialdyne releases ADMAX as a lyophilized peptide against a ≥ 99.0% HPLC main-peak specification, with a batch-specific Certificate of Analysis covering RP-HPLC purity, mass-spec identity, water content, residual solvents, and endotoxin. Sequence / identity confirmation is documented on the released lot.
Applications & buyer fit
Buyers for longevity-class peptides span research labs working on telomere, collagen, and circadian-rhythm models, plus cosmetic-formulation OEMs incorporating peptides like GHK-Cu into anti-aging finished products. Copper peptides in particular require attention to chelator-free water and EDTA-free buffers in downstream formulation work, incompatibility there is the most common cause of "the peptide didn't work" support tickets in this class.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Copper peptides require chelator-free water and EDTA-free buffers in downstream formulation work.
Primary buyer fit: academic and contract research laboratories.
Specifications
Regulatory note
Research-use-only reference material; not for human or veterinary use.
Frequently asked questions
ADMAX exists in the catalogue primarily to support research-buyer procurement systems that reference this Semax/P21-family analog by its common upstream trade name. For direct end-buyers who need a single, well-characterized compound for clean documentation chains, the recommended path is to order Semax or P21 directly instead. ADMAX remains useful when a buyer's downstream workflow specifically needs to reference the trade name itself, or wants to research the adamantane-modified variant as its own subject.
Trade-name peptide products are an established commercial pattern in the Russian and Eastern European peptide-supply ecosystem, where individual upstream manufacturers brand specific preparations under marketing names rather than chemical designations. ADMAX is one such reference-name product, generally understood in the trade as the Semax/P21-family adamantane analog described above, though the upstream manufacturer's exact synthesis process and molecular specification are not independently published. Peprimo distributes the released material with batch-level identity confirmation but doesn't independently re-characterize the formulation. Buyers researching the Russian-school peptide framework specifically may find this product relevant to their literature; buyers building Western-regulated workflows generally should prefer named-API SKUs like Semax or P21.
